Xuan Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuan Jiang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Shenglong Zhu
Wuxi School of Medicine, Jiangnan University, Wuxi, China
3 shared publications - Xinmiao Liang
State Key Laboratory of Phytochemistry and Natural Medicines Dalian Institute of Chemical Physics Chinese Academy of Sciences Dalian China
3 shared publications - Donghai Xia
Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
2 shared publications - Dongping Yu
Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China
2 shared publications - Gaowa Jin
Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China
2 shared publications - Han Zhou
Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China
2 shared publications
Latest Publications
- 30 July 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (31) , 24361-24376
Phyllanthus emblica Polysaccharide Improves Metabolic Associated Fatty Liver Disease by Regulating Gut–Liver Axis through Akkermansia and Short-Chain Fatty Acid Receptors
This study investigated the therapeutic effects of PEP-2, a 348.45 kDa pectin isolated from Phyllanthus emblica, against metabolic-associated fatty liver disease (MAFLD). Characterized as a homogalacturonan with minor rhamnogalacturonan I, PEP-2 consists of galacturonic acid, galactose, rhamnose, and arabinose. In high-fat diet-induced mice, PEP-2 significantly improved metabolic phenotypes, reducing obesity, insulin resistance, and hepatic steatosis. Mechanistically, PEP-2 modulated the gut–liver axis by enriching Akkermansia and enhancing short-chain fatty acid (SCFA) production. These changes were associated with increased colonic mRNA expression of SCFA receptor-related genes, including GPR41, GPR43, and GPR109A, and favorable regulation of hepatic lipid metabolism-related genes, including AMPK, PPARα, and CPT1. In vitro, PEP-2 promoted Akkermansia muciniphila growth, while its fermentation products effectively reduced lipid accumulation in cell models. These findings support a microbiota-SCFA-associated mechanism underlying the beneficial effects of PEP-2 and highlight its potential as a prebiotic candidate for functional food development against metabolic disorders.
- 30 July 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (31) , 24361-24376
Phyllanthus emblica Polysaccharide Improves Metabolic Associated Fatty Liver Disease by Regulating Gut–Liver Axis through Akkermansia and Short-Chain Fatty Acid Receptors
This study investigated the therapeutic effects of PEP-2, a 348.45 kDa pectin isolated from Phyllanthus emblica, against metabolic-associated fatty liver disease (MAFLD). Characterized as a homogalacturonan with minor rhamnogalacturonan I, PEP-2 consists of galacturonic acid, galactose, rhamnose, and arabinose. In high-fat diet-induced mice, PEP-2 significantly improved metabolic phenotypes, reducing obesity, insulin resistance, and hepatic steatosis. Mechanistically, PEP-2 modulated the gut–liver axis by enriching Akkermansia and enhancing short-chain fatty acid (SCFA) production. These changes were associated with increased colonic mRNA expression of SCFA receptor-related genes, including GPR41, GPR43, and GPR109A, and favorable regulation of hepatic lipid metabolism-related genes, including AMPK, PPARα, and CPT1. In vitro, PEP-2 promoted Akkermansia muciniphila growth, while its fermentation products effectively reduced lipid accumulation in cell models. These findings support a microbiota-SCFA-associated mechanism underlying the beneficial effects of PEP-2 and highlight its potential as a prebiotic candidate for functional food development against metabolic disorders.
- Open Access
- 20 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2793
Identification of a Novel NPC1L1 Inhibitor from Danshen and Its Role in Nonalcoholic Fatty Liver Disease
Danshen, a well-known traditional Chinese medicine (TCM), has gained increasing attention for its protective effects on nonalcoholic fatty liver disease (NAFLD). However, the molecular mechanisms underlying these effects remain to be elucidated. Niemann-Pick C1-like 1 (NPC1L1), a key transporter mediating intestinal cholesterol absorption, has emerged as a critical target for NAFLD treatment. This study aimed to screen for NPC1L1 inhibitors from Danshen and investigate their therapeutic effects on NAFLD. We established a high-throughput screening platform using stable Caco2 cell lines expressing human NPC1L1 (hL1-Caco2) and discovered that tanshinones (Tans), the liposoluble components of Danshen, inhibited NPC1L1-mediated cholesterol absorption in hL1-Caco2 cells. Additionally, Tans treatment reduced hepatic steatosis in high-fat diet (HFD)-fed mice. To identify the active compounds in Tans, activity-oriented separation was performed by integrating the high-throughput screening platform and two-dimensional chromatographic techniques. Ultimately, cryptotanshinone (CTS) was identified as a novel NPC1L1 inhibitor and significantly decreased hepatic steatosis in HFD-fed mice. Molecular docking and dynamics simulation showed that CTS stably bound with NPC1L1, where TRP383 acted as the key amino acid. Taken together, this study demonstrates, for the first time, that CTS, a liposoluble compound from Danshen, is a novel NPC1L1 inhibitor. Our findings suggest that the inhibitory effect of CTS against NPC1L1-mediated intestinal cholesterol absorption may be a potential mechanism, contributing to its alleviation of NAFLD in mice.
- 20 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2793
Open AccessIdentification of a Novel NPC1L1 Inhibitor from Danshen and Its Role in Nonalcoholic Fatty Liver Disease
Danshen, a well-known traditional Chinese medicine (TCM), has gained increasing attention for its protective effects on nonalcoholic fatty liver disease (NAFLD). However, the molecular mechanisms underlying these effects remain to be elucidated. Niemann-Pick C1-like 1 (NPC1L1), a key transporter mediating intestinal cholesterol absorption, has emerged as a critical target for NAFLD treatment. This study aimed to screen for NPC1L1 inhibitors from Danshen and investigate their therapeutic effects on NAFLD. We established a high-throughput screening platform using stable Caco2 cell lines expressing human NPC1L1 (hL1-Caco2) and discovered that tanshinones (Tans), the liposoluble components of Danshen, inhibited NPC1L1-mediated cholesterol absorption in hL1-Caco2 cells. Additionally, Tans treatment reduced hepatic steatosis in high-fat diet (HFD)-fed mice. To identify the active compounds in Tans, activity-oriented separation was performed by integrating the high-throughput screening platform and two-dimensional chromatographic techniques. Ultimately, cryptotanshinone (CTS) was identified as a novel NPC1L1 inhibitor and significantly decreased hepatic steatosis in HFD-fed mice. Molecular docking and dynamics simulation showed that CTS stably bound with NPC1L1, where TRP383 acted as the key amino acid. Taken together, this study demonstrates, for the first time, that CTS, a liposoluble compound from Danshen, is a novel NPC1L1 inhibitor. Our findings suggest that the inhibitory effect of CTS against NPC1L1-mediated intestinal cholesterol absorption may be a potential mechanism, contributing to its alleviation of NAFLD in mice.
- Open Access
- 30 January 2025
- Published by MDPI AG in Preprints.org
Cryptotanshinone Alleviates Nonalcoholic Fatty Liver Disease by Inhibiting NPC1L1-Mediated Intestinal Cholesterol Absorption
Danshen, a well-known traditional Chinese medicine (TCM), has gained increasing attention due to the protective effects on nonalcoholic fatty liver disease (NAFLD). However, the molecular basis and working mechanism remain to be elucidated. Niemann-Pick C1-like 1 (NPC1L1) is the crucial target mediating intestinal cholesterol absorption and its inactivation has been shown to alleviate NAFLD. Thus, this study aimed to screen NPC1L1 inhibitors in Danshen and investigate the therapeutic effects on NAFLD . A high-throughput screening platform based on the stable Caco2 cell lines expressing human-NPC1L1 (hL1-Caco2) was developed, and we found that tanshinones (Tans), the liposoluble components in Danshen, inhibited NPC1L1-mediated cholesterol absorption in hL1-Caco2 cells . The hepatic steatosis in high-fat diet (HFD)-fed mice was also reduced by Tans treatment. To find the active compounds in Tans, activity-oriented separation was performed by combining the high-throughput screening platform and two-dimensional chromatographic techniques. Ultimately, c ryptotanshinone (CTS) was identified as a novel NPC1L1 inhibitor and profoundly decreased hepatic steatosis in HFD-fed mice. The binding modes and stability between CTS and NPC1L1 were confirmed by molecular docking and dynamics simulation . Taken together, our findings demonstrate for the first time that CTS, the liposoluble compound in Danshen, alleviates NAFLD by inhibiting NPC1L1-mediated intestinal cholesterol absorption , suggesting that inhibition of NPC1L1 with CTS may be a potential strategy for the treatment of NAFLD.
- 30 January 2025
- Published by MDPI AG in Preprints.org
Open AccessCryptotanshinone Alleviates Nonalcoholic Fatty Liver Disease by Inhibiting NPC1L1-Mediated Intestinal Cholesterol Absorption
Danshen, a well-known traditional Chinese medicine (TCM), has gained increasing attention due to the protective effects on nonalcoholic fatty liver disease (NAFLD). However, the molecular basis and working mechanism remain to be elucidated. Niemann-Pick C1-like 1 (NPC1L1) is the crucial target mediating intestinal cholesterol absorption and its inactivation has been shown to alleviate NAFLD. Thus, this study aimed to screen NPC1L1 inhibitors in Danshen and investigate the therapeutic effects on NAFLD . A high-throughput screening platform based on the stable Caco2 cell lines expressing human-NPC1L1 (hL1-Caco2) was developed, and we found that tanshinones (Tans), the liposoluble components in Danshen, inhibited NPC1L1-mediated cholesterol absorption in hL1-Caco2 cells . The hepatic steatosis in high-fat diet (HFD)-fed mice was also reduced by Tans treatment. To find the active compounds in Tans, activity-oriented separation was performed by combining the high-throughput screening platform and two-dimensional chromatographic techniques. Ultimately, c ryptotanshinone (CTS) was identified as a novel NPC1L1 inhibitor and profoundly decreased hepatic steatosis in HFD-fed mice. The binding modes and stability between CTS and NPC1L1 were confirmed by molecular docking and dynamics simulation . Taken together, our findings demonstrate for the first time that CTS, the liposoluble compound in Danshen, alleviates NAFLD by inhibiting NPC1L1-mediated intestinal cholesterol absorption , suggesting that inhibition of NPC1L1 with CTS may be a potential strategy for the treatment of NAFLD.
- Open Access
Endogenous n-3 PUFAs Improve Non-Alcoholic Fatty Liver Disease through FFAR4-Mediated Gut–Liver Crosstalk
The gut–liver axis plays a key role in the development and progression of non-alcoholic fatty liver disease (NAFLD). Due to the complexity and incomplete understanding of the cross-talk between the gut and liver, effective therapeutic targets are largely unknown. Free fatty acid receptors (FFARs) may bridge the cross-talk between the gut and liver. FFAR4 has received considerable attention due to its important role in lipid metabolism. However, the role of FFAR4 in this cross talk in NAFLD remains unclear. In this study, mice with high endogenous n-3 PUFAs but FFAR4 deficiency were generated by crossbreeding Fat-1 and FFAR4 knockout mice. FFAR4 deficiency blocked the protective effects of high endogenous n-3 PUFAs on intestinal barrier dysfunction and hepatic steatosis. In addition, FFAR4 deficiency decreased gut microbiota diversity and enriched Rikenella, Anaerotruncus, and Enterococcus, and reduced Dubosiella, Ruminococcaceae UCG-010, Ruminococcaceae UCG-014, Coriobacteriaceae UCG-002, Faecalibaculum, Ruminococcaceae UCG-009, and Akkermansia. Notably, FFAR4 deficiency co-regulated pantothenic acid and CoA biosynthesis, β-alanine metabolism, and sphingolipid metabolism pathways in the gut and liver, potentially associated with the aggravation of NAFLD. Together, the beneficial effects of n-3 PUFAs on the gut and liver were mediated by FFAR4, providing insights on the role of FFAR4 in the treatment of NAFLD through the gut–liver axis.
Open AccessEndogenous n-3 PUFAs Improve Non-Alcoholic Fatty Liver Disease through FFAR4-Mediated Gut–Liver Crosstalk
The gut–liver axis plays a key role in the development and progression of non-alcoholic fatty liver disease (NAFLD). Due to the complexity and incomplete understanding of the cross-talk between the gut and liver, effective therapeutic targets are largely unknown. Free fatty acid receptors (FFARs) may bridge the cross-talk between the gut and liver. FFAR4 has received considerable attention due to its important role in lipid metabolism. However, the role of FFAR4 in this cross talk in NAFLD remains unclear. In this study, mice with high endogenous n-3 PUFAs but FFAR4 deficiency were generated by crossbreeding Fat-1 and FFAR4 knockout mice. FFAR4 deficiency blocked the protective effects of high endogenous n-3 PUFAs on intestinal barrier dysfunction and hepatic steatosis. In addition, FFAR4 deficiency decreased gut microbiota diversity and enriched Rikenella, Anaerotruncus, and Enterococcus, and reduced Dubosiella, Ruminococcaceae UCG-010, Ruminococcaceae UCG-014, Coriobacteriaceae UCG-002, Faecalibaculum, Ruminococcaceae UCG-009, and Akkermansia. Notably, FFAR4 deficiency co-regulated pantothenic acid and CoA biosynthesis, β-alanine metabolism, and sphingolipid metabolism pathways in the gut and liver, potentially associated with the aggravation of NAFLD. Together, the beneficial effects of n-3 PUFAs on the gut and liver were mediated by FFAR4, providing insights on the role of FFAR4 in the treatment of NAFLD through the gut–liver axis.